2.65
0.00 (0.00%)
| Previous Close | 2.65 |
| Open | 2.68 |
| Volume | 7,536,000 |
| Avg. Volume (3M) | 5,400,375 |
| Market Cap | 4,533,116,928 |
| Price / Sales | 20.61 |
| Price / Book | 4.75 |
| 52 Weeks Range |
| Profit Margin | -35.41% |
| Operating Margin (TTM) | -137.98% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | -13.20% |
| Total Debt/Equity (MRQ) | 85.91% |
| Current Ratio (MRQ) | 0.750 |
| Operating Cash Flow (TTM) | -290.37 M |
| Levered Free Cash Flow (TTM) | -150.46 M |
| Return on Assets (TTM) | -11.33% |
| Return on Equity (TTM) | -10.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | LEPU BIO-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| LEPU BIO-B | 5 B | - | - | 4.75 |
| FRONTAGE | 3 B | - | 83.00 | 1.29 |
| ALPHAMAB-B | 3 B | - | - | 1.88 |
| ABBISKO-B | 3 B | - | - | 1.21 |
| CSTONE PHARMA-B | 3 B | - | - | 5.94 |
| GENOR-B | 930 M | - | - | 0.800 |
|
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 62.93% |
| % Held by Institutions | 5.44% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |